Background
==========

Aortic intramural hematoma (IMH) is an important acute aortic syndrome that presents symptoms similar to those of classic aortic dissection. Recent advances in imaging techniques have significantly improved the diagnosis and heightened the clinical understanding of IMH, which accounts for a frequency of 10% to 30% of all acute aortic syndromes \[[@B1]-[@B3]\]. IMH is different from aortic dissection due to its absence of continuous direct flow communication through intimal tear; It shows very dynamic process in the early phase and the natural history of IMH is not clearly known yet.

IMH is classified as either involving (type A) or not involving (type B) the ascending aorta. The site of IMH is an important parameter to determine prognosis. Patients with type B IMH, like those with type B aortic dissection, are usually treated medically \[[@B4]\]. However, management of patients with type A IMH is controversial. Some reports have recommended early surgery for patients with type A IMH because of their poor prognosis with medical treatment \[[@B5]-[@B7]\]. On the other hand, recent studies have shown favorable results with medical therapy in some type A IMH cases \[[@B8],[@B9]\]. Therefore, we retrospectively analyzed imaging studies, treatment strategies and clinical outcomes of patients with acute IMH from real world registry data.

Method
======

Study patients
--------------

From January 2000 through December 2010, a total of 165 patients with acute IMH were admitted to five medical centers. IMH was defined as a circular or crescent shape, extensive aortic wall hematoma with no evidence of intimal flap or false lumen noted by contrast computed tomographic (CT) scan. The patients were divided into two groups according to the aortic segment afflicted with IMH, whether it was on the ascending thoracic aorta and/or aortic arch (type A, n = 61) or the descending thoracic aorta (type B, n = 104). Clinical features, hospital mortality, and long-term survivals were compared between patients with type A and type B IMH for 2 years.

Data collection and analysis
----------------------------

Chart review was performed, and data were collected with a standardized format that included information on patient demographics, medical history, clinical presentation, physical findings, results of imaging studies, details of medical and surgical treatment, and outcome. Follow-up data were collected by direct telephone interviews and detailed review of all medical records. The cause and date of any death were confirmed by information gathered from the National Population Registry of the Korean National Statistical Office, together with a review of all available clinical records at the time of death. This retrospective study was approved by the Institutional review board of Yeungnam University (IRB No. YUH-13-0362-B3). The need for informed consent was waived by the board.

Statistical analysis
--------------------

Categorical variables are described as number and percent and compared with the chi-squared test, or Fisher exact test as appropriate. Continuous variables are described as mean ± SD. Survival analysis was performed by Kaplan-Meier analysis, and differences in survival between the groups were examined with the log-rank test. To determined predictors for progression of ascending IMH and mortality throughout follow-up period, Cox proportional hazards model was used to estimate the risk of the potential variables. *P* value \< 0.05 (two-sided) was considered statistically significant. Data analyses were performed with SPSS software (version 18.0; SPSS, Inc, Chicago, Ill).

Results
=======

Table [1](#T1){ref-type="table"} summarizes the clinical features of both groups. Mean age (68 ± 10 vs. 67 ± 12, *P* = 0.521), the prevalence of diabetes (6.6% vs. 6.7%, *P* = 0.966), hypertension (60.7% vs. 50.0%. *P* = 0.185), dyslipidemia (36.4% vs. 31.6%, *P* = 0.688), current smoking status (32.8% vs. 28.8%, *P* = 0.595) and time from onset to admission (10.6 ± 16.2 vs. 7.9 ± 11.3, *P* = 0.251) did not show any difference between the two groups. Male gender was more frequently observed in the type B group (37.7% vs. 58.7%, *P* = 0.009). Chest pain was the most prevalent symptom in both groups. Abdominal pain and back pain followed that. Initial systolic blood pressure was higher in the type B group (138 ± 36 vs. 150 ± 36, *P* = 0.042). Diastolic blood pressure (84 ± 21 vs. 86 ± 19, *P* = 0.522) and heart rate (77 ± 18 vs. 77 ± 23, *P* = 0.997) were no statistically significantly different between the two groups. The laboratory findings were also similar in the two groups.Selected treatment modalities and clinical outcomes are summarized in Figure [1](#F1){ref-type="fig"}. In the type A group, 23% (14/61) underwent emergent surgery, and medical treatment was selected for the remaining 47 patients. Among patients who were treated medically at initial presentation, 3 patients underwent surgery during the hospitalization because of the development of hemopericardium, aggravation of pleural effusion and dye leakage detected from follow up CT. After discharge, only one patient received surgery because of the development of aortic dissection. In the type B group, one patient underwent emergent surgery because suspicious penetrating ulcer was seen in CT. Additional 2 patients underwent timely surgery after enlarged aortic diameter (up to 63 mm) and extravasation of dye were seen from follow up CT examination. Most patients with type B (101/104, 97.1%) IMH received medical treatment only. A total of 21 patients who were underwent surgery during 2 years, 20 cases had aorta graft replacement and 1case had hybrid EVAR (endovascular aneurysm repair).

###### 

Clinical characteristics of the patients, by location of aortic intramural hematoma

                                        **Type A (n = 61)**   **Type B (n = 104)**   ***P*value**
  ------------------------------------ --------------------- ---------------------- --------------
  Age, yrs                                    68 ± 10               67 ± 12             0.521
  Sex, male                                 23 (37.7%)             61 (58.7%)           0.009
  Diabetes                                   4 (6.6%)               7 (6.7%)            0.966
  Hypertension                              37 (60.7%)             52 (50.0%)           0.185
  Dyslipidemia                              16 (36.4%)             24 (31.6%)           0.688
  Current smoking                           20 (32.8%)             30 (28.8%)           0.595
  Time from onset to admission (hrs)        10.6 ± 16.2            7.9 ± 11.3           0.251
  **Initial symptoms**                                                                  0.372
   Chest pain                               31 (50.8%)             58 (55.8%)           0.538
   Abdominal pain                           11 (18.0%)             21 (20.2%)           0.735
   Back pain                                10 (16.4%)             19 (18.3%)           0.760
   Loss of consciousness                     2 (3.3%)               3 (2.9%)            1.000
   Dyspnea                                   4 (6.6%)               1 (1.0%)            0.159
   Others                                    3 (4.9%)               2 (1.2%)            0.360
  **Hemodynamic findings**                                                                 
   Systolic BP, mmHg                         138 ± 36               150 ± 36            0.042
   Diastolic BP, mmHg                         84 ± 21               86 ± 19             0.522
   Heart rate, BPM                            77 ± 18               77 ± 23             0.997
  **Laboratory findings**                                                                  
   Total cholesterol (mg/dL)                 185 ± 53               180 ± 46            0.550
   C-reactive protein (mg/dL)                3.2 ± 4.3             4.7 ± 8.3            0.236
   Creatinine (mg/dL)                       1.20 ± 1.50           0.97 ± 0.34           0.279

![**Diagram of enrolled patients and clinical outcomes.** MTX, medical treatment; STX, surgical treatment.](1471-2261-14-103-1){#F1}

The results of CT were demonstrated in Table [2](#T2){ref-type="table"} according to the time of examinations. Initial, in-hospital follow up, outpatient department follow up CT results were seen. With the use of computerized planimetry, measurements were taken on the basis of the accompanying calibrated scales in the contrast-enhanced CT images. Maximal aortic diameter and maximal hematoma thickness were measured at the level of pulmonary artery bifurcation (Figure [2](#F2){ref-type="fig"}). Maximal ascending aortic diameter in initial CT images was significantly greater in the type A group (47.8 ± 8.2 mm vs. 42.1 ± 5.7 mm, *P* \< 0.001). Maximal descending aortic diameter was greater in the type B group, but there was no significant difference (37.7 ± 7.4 mm vs. 40.0 ± 8.1 mm, *P* = 0.084). Maximal descending hematoma thickness in type A was 10.8 ± 6.8 mm and maximal descending hematoma thickness in type B was 11.6 ± 5.1 mm. Pericardial effusion was common in the type A group (32.8% vs. 3.9%, *P* \< 0.001). In-hospital follow up CT was performed in 78.8% of patients (mean duration 10 ± 7 days). Among them, 59.6% of type A and 41.0% of type B patients showed a decreasing trend of hematoma thickness. There were no significant differences of hematoma thickness (less than 2 mm) compared to initial CT in the 34.0% of type A and 50.0% of type B patients. Progression to aortic dissection was common in type A patients (12.8% vs. 3.6%, *P* = 0.069). Outpatient department follow up CT was performed only in 58.2%. However, information from the National Population Registry of the Korean National Statistical Office and direct telephone interview confirmed that other patients were asymptomatic and in stable condition except the person who died. To determine the independent predictors for progression of type A IMH throughout the follow-up period, Cox regression analysis was performed. There was no significant predictor of the progression of IMH. However, aortic hematoma thickness greater than 10 mm was associated with increased mortality (odds ratio, 9.23; 95% Confidence interval (CI), 1.30 to 65.4; *P* = 0.026) (Table [3](#T3){ref-type="table"}).

###### 

The results of CT examinations

                                                **Type A (n = 61)**   **Type B (n = 104)**   ***P*value**
  -------------------------------------------- --------------------- ---------------------- --------------
  **Initial computed tomography**                                                                  
   Maximal ascending aortic diameter, mm            47.8 ± 8.2             42.1 ± 5.7          \< 0.001
   Maximal descending aortic diameter, mm           37.7 ± 7.4             40.0 ± 8.1           0.084
   Maximal ascending hematoma thickness, mm         10.8 ± 6.8                 \-              \< 0.001
   Maximal descending hematoma thickness, mm         9.9 ± 5.0             11.6 ± 5.1           0.042
   Pleural effusion                                 14 (23.0%)             22 (21.4%)           0.812
   Pericardial effusion                             20 (32.8%)              4 (3.9%)           \< 0.001
  **In-hospital follow up CT**                                                                     
   Follow-up CT duration, days                        10 ± 7                 9 ± 7              0.483
   Follow-up CT study                               47 (77.0%)             84 (80.8%)           0.568
    Decreased hematoma                              28 (59.6%)             34 (41.0%)           0.041
    Increased hematoma                               3 (6.4%)               7 (8.4%)            0.480
    Progression to aortic dissection                 6 (12.8%)              3 (3.6%)            0.069
    No change\*                                     16 (34.0%)             42 (50.0%)           0.068
  **Outpatient Department follow up CT**                                                           
   Follow-up CT duration, days                       452 ± 724             318 ± 453            0.267
   Follow-up CT study                               38 (62.3%)             58 (55.8%)           0.412
    Decreased hematoma                              29 (78.4%)             48 (82.8%)           0.401
    Increased hematoma                               3 (7.9%)               4 (6.9%)            1.000
    Progression to aortic dissection                 5 (13.2%)              5 (8.6%)            0.510
    No change\*                                      6 (15.8%)             6 (10.3%)            0.430

\*No change; Change of hematoma thickness is less than 2 mm compared to initial CT.

![**Measurement methods of intramural hematoma of the aorta.** Maximal aortic diameter **(A)** and maximal hematoma thickness **(B)** were measured at the level of pulmonary artery bifurcation. AD, Maximal ascending aortic diameter; AH, Maximal ascending hematoma thickness; DD, Maximal descending aortic diameter; DH, Maximal descending hematoma thickness; PA, Pulmonary artery.](1471-2261-14-103-2){#F2}

###### 

Predictors of 2-year mortality by Cox regression analysis

                                                   **Odds ratio**   **95% confidence interval**   ***P*value**
  ----------------------------------------------- ---------------- ----------------------------- --------------
  Age \> 70 years                                       1.64               0.23 - 11.78              0.623
  Diabetes                                               0                       0                   0.987
  Hypertension                                          2.81               0.42 - 18.61              0.285
  Dyslipidemia                                          0.26                0.02 - 2.99              0.278
  Time from onset to admission \> 24 hrs                1.67               0.25 - 11.09              0.600
  Initial systolic BP \< 90 mmHg                        3.00               0.04 - 202.96             0.609
  Pleural effusion at CT                                0.38                0.02 - 0.68              0.509
  Pericardial effusion at CT                            3.51               0.18 - 67.84              0.405
  Maximal ascending aortic diameter \> 55 mm            1.43               0.17 - 11.69              0.740
  Maximal ascending hematoma thickness \> 10 mm         9.23                1.30 - 65.4              0.026

Table [4](#T4){ref-type="table"} shows treatment strategy and clinical outcomes according to location of IMH. Patients receiving emergent surgery had been hospitalized longer than those receiving medical therapy in both type A (29 ± 14 vs. 16 ± 8, *P* = 0.004) and type B (26 vs. 17 ± 13, *P* = 0.492) groups. During the 2-year follow up period, progression to aortic dissection (18.0% vs. 6.7%, *P* = 0.037) and surgical treatment (29.5% vs. 2.9%, *P* \< 0.001) were common in type A. However, there were no significant difference in-hospital mortality (4.9% vs. 2.9%, *P* = 0.671) and 2-year mortality (13.1% vs. 11.5%, *P* = 0.765) between type A and B. In the type A patients, there were no significant difference in in-hospital mortality (7.1% of surgery vs. 4.3% of medical, *P* = 0.428) and 2-year mortality (7.1% of surgery vs. 14.9% of medical, *P* = 0.450) in terms of initial treatment strategy (Figure [3](#F3){ref-type="fig"}).

###### 

Treatment strategy and clinical outcomes according to location of aortic intramural hematoma

                                                  **Type A (n = 61)**   **Type B (n = 104)**   ***P*value**
  ---------------------------------------------- --------------------- ---------------------- --------------
  **Admission duration (days)**                         19 ± 11               17 ± 13             0.535
   Emergency surgery (within 24 hrs)                    29 ± 14                  26               0.855
   Medical therapy and timely surgery                   16 ± 8                17 ± 13             0.404
  **In-hospital mortality**                           3/61 (4.9%)          3 /104 (2.9%)          0.671
   Emergency surgery (within 24 hrs)                  1/14 (7.1%)             0/1 (0%)            1.000
   Medical therapy and timely surgery                 2/47 (4.3%)           3/103 (2.9%)          0.649
  **2-year mortality**                               8/61 (13.1%)          12/104 (11.5%)         0.765
   Emergency surgery (within 24 hrs)                  1/14 (7.1%)             0/1 (0%)            1.000
   Medical therapy and timely surgery                7/47 (14.9%)          12/103 (11.7%)         0.580
  Progression to aortic dissection for 2 years        11 (18.0%)              7 (6.7%)            0.037
  Surgical treatment for 2 years                      18 (29.5%)              3 (2.9%)           \< 0.001

![**Survival rates of type A acute intramural hematoma according to the initial treatment strategy. (A)** In-hospital survival rates were 92.9% who received emergency surgery vs. 95.7% who received medical therapy and timely surgery in selected patients (*P* = 0.428). **(B)** During 2-year follow up, Survival rates were 92.9% who received emergency surgery vs. 85.1% who received medical therapy and timely surgery in selected patients (*P* = 0.450).](1471-2261-14-103-3){#F3}

Discussion
==========

Aortic IMH, known as a variant form of aortic dissection, is characterized by the absence of intimal tear and direct flow communication between true and false lumen. It results from spontaneous rupture of aortic vasa vasorum or penetrating atherosclerotic ulcer \[[@B10]-[@B12]\]. Recent advances in noninvasive imaging such as computed tomography (CT), magnetic resonance (MR) imaging, and transesophageal echocardiography (TEE) are used to identify a variant of aortic dissection and have further emphasized the importance of early diagnosis of acute aortic syndrome. Among them, CT is widely used as the imaging modality of first choice for the assessment of thoracic aortic disease and can be used even in clinically unstable patients. Moreover, various diameters of the aorta can be measured easily in serial CT images such as aortic diameter and aortic wall thickness \[[@B1],[@B13]-[@B15]\]. There are several studies that propose these parameters as a prognostic factor. Maximum aortic diameter ≥ 50 mm, hematoma thickness ≥ 11 mm are supposed to predict adverse clinical outcome \[[@B16],[@B17]\]. Our study also showed that patients with larger hematoma thickness (≥10 mm) at initial CT were considered as a high risk group. Perhaps this is because larger hematoma thickness might represent a larger blood accumulation in the aortic wall, which could increase the risk of development of aortic dissection or perivascular leakage.

The management of IMH of the aorta remains controversial. Existing studies have suggested that different therapeutic strategy based on the affected area be used as the site of IMH is an important parameter to determine prognosis. Usually patients with distal IMH involving the descending aorta (Stanford type B) treated medically and their favorable prognosis is demonstrated in many studies. Kaji et al. reported long-term clinical course of patients with type B IMH. In their study, treated initially with medical therapy, type B IMH shows lower in-hospital mortality (0% vs. 14%, *P* = 0.006) and higher 5-year survival rates (97% vs. 79%, *P* = 0.009) compared with type B aortic dissection \[[@B18]\]. Song et al. reported that absence of persistent flow communication in the false lumen resulted in a favorable remodeling process in IMH affecting distal descending aorta \[[@B19]\]. It has been reported that even type B IMH could progress to overt dissection or aortic rupture \[[@B20]\]. Medical therapy is generally accepted in initial management of type B IMH.

However, management of patients with type A IMH is controversial. Some studies reported that medically treated type A IMH patients showed worse prognosis than surgically treated patients. Because short term prognosis is serious in IMH involving the ascending aorta owing to frequent progression to aortic rupture, dissection or aneurysm, they insist that surgical repair improves outcome in type A patients \[[@B7],[@B21]\]. However, the progression of type A IMH appears to be more benign than that of aortic dissection and studies from Asian countries reported low mortality rates in medically treated proximal IMH. Song et al. reported that among medically treated type A IMH patients, 67% showed disappearance of hematoma and 78% survived during 3-year follow-up \[[@B9],[@B22]\]. In another study of type A patients treated initially with supportive medical therapy, in-hospital mortality rate was significantly lower (7% vs. 34%, *P* = 0.004) and 5-year survival rates was significantly higher (90% vs. 62%, P = 0.004) than aortic dissection group \[[@B23]\]. Another recent study conducted for North American and European showed that the majority of type A IMH patients (84.4%) received surgical treatment. Even though there was no direct comparison between surgically treated and medically treated type A IMH, the mortality in medically treated group (40.0%) was much higher than that of surgically treated group (24.1%) \[[@B24]\]. Although the exact cause is unknown, IMH is diagnosed much more frequently and has better outcomes in Japan/Korea than North America/Europe. It is possibly due to the heightened awareness of the IMH diagnosis and detect more benign variant of IMH. In addition, genetic, dietary, or environmental factors may influence geographic variation \[[@B25]\].

Previous studies have shown that medical treatment alone was not enough to manage all type A IMH patients. Patients with recurrent pain, progression to overt type A dissection, or progressive aortic dilatation during medical follow-up should converted to surgery \[[@B26]\]. To monitor the morphological changes and development of delayed vascular complications such as that, regular follow-up imaging will be essential \[[@B27]\]. In addition, recent technical improvements in surgery for acute aortic syndrome have resulted in reduced operative mortality. Moreover, delayed surgery did not increase mortality \[[@B8],[@B28]\]. Thus, supportive medical treatment with frequent follow-up imaging studies and timed surgical repair can be a rational therapeutic strategy in management of type A IMH. In this study, we analyzed 165 Asian patients with IMH, and this is one of the largest studies of IMH to date. There were also no significant difference in in-hospital mortality and 2-year mortality according to initial treatment strategy. Based on our data, medical therapy with or without timely operation resulted in favorable long-term results similar to other studies from Asia.

There are several limitations in our study. First, it was a retrospective analysis of data and not a randomized study. There were no definite criteria for surgical therapy. Second, the rates of CT follow-up were low and this may underestimate progression of IMH. Third, there were a relatively small number of patients who developed aortic dissections or who died. Thus, we did not have adequate power to identify risk factors of these outcomes. Fourth, we did not take into account the variations of normal aortic dimensions related to age.

Conclusions
===========

For real world practice in Korea, most of IMH patients were treated medically at presentation and showed favorable outcomes. Thus, even in type A acute IMH, early medical treatment with alternative surgical conversion for selected, complicated cases would be a favorable treatment option. Moreover it can also reduce medical costs through the shorter hospitalization period and the reduction of operation charge. Longer follow-up observation of more patients is needed to assess the real impact of the initial hematoma thickness on the prognosis of IMH and timing of surgical intervention.
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